<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2022-05-17">17 May 2022</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Andrea</forename><forename type="middle">K</forename><surname>Ühnl</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Medical and Molecular Genetics</orgName>
								<orgName type="department" key="dep2">Faculty of Life Sciences and Medicine</orgName>
								<orgName type="institution">King&apos;s College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<orgName type="institution">Charit é University Hospital Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><forename type="middle">J M</forename><surname>Valk</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution">Erasmus University Medical Center</orgName>
								<address>
									<settlement>Rotterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mathijs</forename><forename type="middle">A</forename><surname>Sanders</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution">Erasmus University Medical Center</orgName>
								<address>
									<settlement>Rotterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Adam</forename><surname>Ivey</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Medical and Molecular Genetics</orgName>
								<orgName type="department" key="dep2">Faculty of Life Sciences and Medicine</orgName>
								<orgName type="institution">King&apos;s College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Robert</forename><forename type="middle">K</forename><surname>Hills</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Haematology</orgName>
								<orgName type="institution">Cardiff University School of Medicine</orgName>
								<address>
									<settlement>Cardiff</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ken</forename><forename type="middle">I</forename><surname>Mills</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Centre for Cancer Research and Cell Biology</orgName>
								<orgName type="institution">Queen&apos;s University Belfast</orgName>
								<address>
									<settlement>Belfast</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rosemary</forename><forename type="middle">E</forename><surname>Gale</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Haematology</orgName>
								<orgName type="institution">University College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><forename type="middle">F</forename><surname>Kaiser</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<orgName type="institution">Charit é University Hospital Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Richard</forename><surname>Dillon</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Medical and Molecular Genetics</orgName>
								<orgName type="department" key="dep2">Faculty of Life Sciences and Medicine</orgName>
								<orgName type="institution">King&apos;s College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Melanie</forename><surname>Joannides</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Medical and Molecular Genetics</orgName>
								<orgName type="department" key="dep2">Faculty of Life Sciences and Medicine</orgName>
								<orgName type="institution">King&apos;s College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Amanda</forename><surname>Gilkes</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Haematology</orgName>
								<orgName type="institution">Cardiff University School of Medicine</orgName>
								<address>
									<settlement>Cardiff</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Torsten</forename><surname>Haferlach</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">MLL Munich Leukemia Laboratory</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Susanne</forename><surname>Schnittger</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">MLL Munich Leukemia Laboratory</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Estelle</forename><surname>Duprez</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Centre de Recherche en Canc érologie de Marseille</orgName>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">INSERM U1068</orgName>
								<orgName type="institution" key="instit1">Centre National de la Recherche Scientifique UMR7258</orgName>
								<orgName type="institution" key="instit2">Institut Paoli-Calmettes</orgName>
								<orgName type="institution" key="instit3">Aix Marseille University</orgName>
								<address>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><forename type="middle">C</forename><surname>Linch</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Haematology</orgName>
								<orgName type="institution">University College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ruud</forename><surname>Delwel</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution">Erasmus University Medical Center</orgName>
								<address>
									<settlement>Rotterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bob</forename><forename type="middle">L</forename><surname>Öwenberg</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution">Erasmus University Medical Center</orgName>
								<address>
									<settlement>Rotterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Claudia</forename><forename type="middle">D</forename><surname>Baldus</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<orgName type="institution">Charit é University Hospital Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ellen</forename><surname>Solomon</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Medical and Molecular Genetics</orgName>
								<orgName type="department" key="dep2">Faculty of Life Sciences and Medicine</orgName>
								<orgName type="institution">King&apos;s College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alan</forename><forename type="middle">K</forename><surname>Burnett</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Haematology</orgName>
								<orgName type="institution">Cardiff University School of Medicine</orgName>
								<address>
									<settlement>Cardiff</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Grimwade</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Medical and Molecular Genetics</orgName>
								<orgName type="department" key="dep2">Faculty of Life Sciences and Medicine</orgName>
								<orgName type="institution">King&apos;s College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2022-05-17">17 May 2022</date>
						</imprint>
					</monogr>
					<idno type="MD5">BE525D89D91A272283966CB48EBB81CC</idno>
					<idno type="DOI">10.1182/blood-2014-12-</idno>
					<note type="submission">Submitted November 30, 2014; accepted March 11, 2015. Prepublished online as Blood First Edition paper, March 24, 2015;</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:32+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The gene CXXC5 on 5q31 is frequently deleted in acute myeloid leukemia (AML) with del(5q), suggesting that inactivation of CXXC5 might play a role in leukemogenesis.</s><s>Here, we investigated the functional and prognostic implications of CXXC5 expression in AML.</s><s>CXXC5 mRNA was downregulated in AML with MLL rearrangements, t(8;21) and GATA2 mutations.</s><s>As a mechanism of CXXC5 inactivation, we found evidence for epigenetic silencing by promoter methylation.</s><s>Patients with CXXC5 expression below the median level had a lower relapse rate (45% vs 59%; P 5 .007)</s><s>and a better overall survival (OS, 46% vs 28%; P &lt; .001)</s><s>and event-free survival (EFS, 36% vs 21%; P &lt; .001) at 5 years, independent of cytogenetic risk groups and known molecular risk factors.</s><s>In gene-expression profiling, lower CXXC5 expression was associated with upregulation of cell-cycling genes and codownregulation of genes implicated in leukemogenesis (WT1, GATA2, MLL, DNMT3B, RUNX1).</s><s>Functional analyses demonstrated CXXC5 to inhibit leukemic cell proliferation and Wnt signaling and to affect the p53-dependent DNA damage response.</s><s>In conclusion, our data suggest a tumor suppressor function of CXXC5 in AML.</s><s>Inactivation of CXXC5 is associated with different leukemic pathways and defines an AML subgroup with better outcome.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Outcome of younger adults (,60 years) with acute myeloid leukemia (AML) remains poor, with survival rates of only 40% to 45%, <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref> highlighting the need for new therapeutic strategies.</s><s>Several prognostically significant recurrent mutations and aberrant signaling pathways have been identified in AML, which allowed for improved risk stratification and development of targeted therapies.</s><s>Further refinement of relevant molecular alterations in different AML subgroups might eventually result in more individual treatment approaches and potentially improve outcome.</s></p><p><s>The CXXC-type zinc finger protein CXXC5 has exhibited tumorsuppressor functions in solid tumor cells. <ref type="bibr" target="#b2">3</ref></s><s>In addition, CXXC5 has been demonstrated to negatively regulate the canonical Wnt/b-catenin signaling pathway in nontumorous tissues. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b4">5</ref></s><s>Wnt activation has been implicated in leukemic transformation <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7</ref> and was shown to promote proliferation and survival of leukemic cells in vitro. <ref type="bibr" target="#b7">8</ref></s><s>he CXXC motif is found in a small number of proteins, most of which are involved in epigenetic modification, like the DNA methyltransferase DNMT1 (CXXC9), histone methyltransferases (MLL [CXXC7], MLL2 [CXXC12]), the methylcytosine dioxygenase TET1 (CXXC6), and histone demethylases (KDM2A [CXXC8], KDM2B [CXXC2]).</s><s>MLL plays an important role in development and progression of acute leukemias. 9</s><s>DNMT1 10-12 and TET1 <ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b12">13</ref> have more recently been related to leukemogenesis in addition to enzyme family members DNMT3A <ref type="bibr" target="#b13">14</ref> and TET2. <ref type="bibr" target="#b14">15</ref></s><s>Inactivation of CXXC4, the paralog of CXXC5, has been associated with tumor progression and inferior outcome in renal cell carcinoma. <ref type="bibr" target="#b15">16</ref></s><s>XXC5 is located on 5q31.2, a region recurrently deleted in AML, and was found to be downregulated in AML with del(5q). <ref type="bibr" target="#b16">17</ref></s><s>In addition, somatic microdeletions containing CXXC5 (and CXXC4) have been described in patients with AML and myelodysplastic syndrome (MDS), <ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b19">19</ref> further supporting involvement of CXXC5 in leukemogenesis.</s><s>CXXC5 has been demonstrated to be induced by treatment with all-trans retinoic acid in acute promyelocytic leukemia (APL). <ref type="bibr" target="#b20">20</ref></s><s>t was further shown that CXXC5 expression increases during cytokine-driven maturation of hematopoietic precursors, indicating a functional role of CXXC5 in normal myelopoiesis. <ref type="bibr" target="#b20">20</ref></s><s>A recent study reported heterogeneous CXXC5 expression levels in a small cohort of de novo and secondary AML and suggested an impact of CXXC5 expression on chemosensitivity and outcome. <ref type="bibr" target="#b21">21</ref></s><s>iven the functional implications of CXXC5 in normal myeloid and leukemic development, its putative role as a tumor suppressor, and its potential prognostic relevance, CXXC5 is an interesting candidate gene in myeloid malignancies.</s><s>Therefore, we aimed to study the functional and prognostic impact of CXXC5 in AML.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient samples</head><p><s>We analyzed microarray-based CXXC5 expression in 529 diagnostic bone marrow (BM) mononuclear cell samples from consecutive AML patients enrolled in Dutch-Belgian-Swiss Hemato-Oncology Cooperative Group (HOVON/SAKK) trials <ref type="bibr" target="#b22">22,</ref><ref type="bibr" target="#b23">23</ref>   15-77]), CXXC5 mRNA expression was also assessed by reversetranscriptase quantitative polymerase chain reaction (RT-qPCR) and compared with 19 CD34 1 BM samples obtained from patients undergoing hip replacement (median age, 64 years).</s><s>We also analyzed microarray data from 351 normal karyotype (NK)-AML patients derived from the Microarray Innovations in LEukemia (MILE) study <ref type="bibr" target="#b24">24</ref> to minimize confounding by cytogenetic alterations.</s></p><p><s>Because CXXC5 is a potential downstream target of GATA2, diagnostic material from 17 cases with GATA2-mutated AML was obtained from the National Cancer Research Institute AML trials tissue bank at University College London and the MLL Munich Leukemia Laboratory.</s><s>Genomic DNA for mutational analyses was available for 84 cases from the UK MRC AML15 trial; pyrosequencing of the CXXC5 promoter was conducted in 46 cases.</s></p><p><s>Informed consent was provided by all patients and donors according to the Declaration of Helsinki and subject to ethical board approval.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell lines and treatment</head><p><s>Leukemic cell lines K562, KG1a, HL60, NB4, U937, and OCI-AML3, as well as 293T cells were obtained from the DSMZ (Braunschweig, Germany) and cultured as recommended.</s></p><p><s>Cells were treated with 5-Aza-29-deoxycytidine (DAC, in dimethyl sulfoxide; Sigma-Aldrich, St Louis, MO) in 12-well plates for 96 hours with 0.2 mM DAC replaced every 24 hours.</s><s>RNA and DNA were extracted using the AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany).</s></p><p><s>For DNA damage experiments, cells were g-irradiated (4 Gy) in full medium at room temperature.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DNA constructs and transfection</head><p><s>Human CXXC5 cDNA was inserted into a pEGFP-C2 expression vector (Clontech, Mountain View, CA) and transfected (see supplemental Material).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>shRNA lentiviral infection</head><p><s>Lentiviral shRNA vectors targeting CXXC5 (pLKO.1;</s><s>clones TRCN0000144558 and TRCN0000142729) were obtained from Open Biosystems (Thermo Fisher, Lafayette, CO).</s><s>Cells were infected with viral particles overnight and selected by puromycin treatment (see supplemental Material).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Wnt reporter assay</head><p><s>K562 and KG1a cells were cotransfected with pEGFP-C2-CXXC5/empty pEGFP-C2, M50 Super 8xTOPFlash vector, and pRL-TK vector (see supplemental Material).</s><s>After 5 hours, cells were seeded in 12-well plates in serum-free medium and incubated overnight.</s><s>Cells were then treated with 100 ng/mL recombinant Wnt3a protein (R&amp;D Systems, Minneapolis, MN), and luciferase activity was measured in triplicates using the Dual-Luciferase Reporter Assay (Promega).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Western blot</head><p><s>Western blot analyses were performed following standard protocols.</s><s>Antibodies and incubation conditions are listed in the supplemental Material.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunofluorescence</head><p><s>Cells were transferred onto a microscope slide by cytospin centrifugation, fixed in 4% paraformaldehyde, and permeabilized in 0.5% Triton X-100.</s><s>Staining was performed under standard conditions using antibodies listed in supplemental Table <ref type="table" target="#tab_1">1</ref>.</s><s>49,6-diamidino-2-phenylindole was added for nuclear staining.</s><s>Confocal microscopy was performed on a Nikon A1Rsi confocal microscope using NIS Elements C software 3.2 (Nikon Instruments, Amsterdam, The Netherlands).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RT-qPCR</head><p><s>RNA was extracted from mononuclear cells using TRIzol reagent (Invitrogen, Carlsbad, CA) and cDNA synthesized with random hexamers and ThermoScript reverse transcriptase (Invitrogen).</s><s>RT-qPCR was conducted as previously described <ref type="bibr" target="#b25">25</ref> with the TaqMan Universal PCR Master Mix on the ABI 7900HT platform (Applied Biosystems, Warrington, United Kingdom), with normalization of CXXC5 expression to ABL, using optimized assays for analysis of leukemia samples established in the Europe Against Cancer program, <ref type="bibr" target="#b26">26</ref> after validating against B2M and GUS housekeeping genes (see supplemental Material).</s><s>Relative expression of genes was determined with the comparative cycle threshold (Ct) method, <ref type="bibr" target="#b25">25</ref> calculating the mean of cycle number difference to the control gene, expressed as 2 ΔCt .</s><s>RNA from Jurkat cells was measured in each run as a calibrator.</s><s>Primers and probes are shown in supplemental Table <ref type="table" target="#tab_1">1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell-cycle analyses</head><p><s>Cells were fixed in 70% ethanol at 4°C overnight, stained with 50 mg/mL propidium iodide and 100 mg/mL RNAse for 30 minutes at 37°C, and immediately analyzed by flow cytometry using FlowJo software 8.7 (Tree Star, Ashland, OR).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Microarray studies</head><p><s>A microarray-based CXXC5-associated gene-expression profile (GEP) was generated from the MILE and HOVON-SAKK cohorts (discussed before) using a HG-U133 Plus 2.0 Affymetrix platform (Santa Clara, CA; see supplemental Material).</s><s>Samples were grouped into quartiles (Q1-Q4) according to the median of the 3 CXXC5 probe sets (222996_s_at, 224516_s_at, 233955_x_at) and patients in the lowest and the highest quartile were compared (Q1 vs Q4).</s></p><p><s>GEP analyses on Wnt-stimulated K562 cells were performed using HG-U133A 2.0 arrays (Affymetrix) as described in the supplemental Material.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mutational profiling and pyrosequencing</head><p><s>Mutational analyses of CXXC5 were performed as described in the supplemental Material.</s><s>To investigate the relationship between CXXC5 expression and methylation status, bisulfite conversion of genomic DNA was performed with the EZ DNA Methylation Kit (Zymo Research, Irvine, CA) and subjected to pyrosequencing (see supplemental Material).</s><s>To investigate whether CXXC5 methylation status correlated with the mutational profile, targeted sequencing was performed using a custom 51-gene panel (HaloPlex Target Enrichment, Agilent Technologies, Santa Clara, CA) on the Illumina HiSeq 2500 platform (see supplemental Material).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Outcome analyses</head><p><s>Outcome analyses were performed on microarray expression data of the HOVON/SAKK cohort (data available for 498 patients, excluding APL) with a median follow-up of 3.4 years.</s><s>Patients were divided into lower and higher CXXC5-expression groups according to the median of the 3 CXXC5 probe sets (discussed before).</s><s>Clinical end points and statistical calculations using SPSS software 18.0 (SPSS, Chicago, IL) are described in the supplemental Material.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CXXC5 expression in AML and association with clinical and molecular characteristics</head><p><s>CXXC5 mRNA expression was determined by RT-qPCR in 231 AML patients from the HOVON/SAKK cohort and 19 normal CD34 1 cells (Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>Median CXXC5 expression of the total AML cohort did not significantly differ from median expression in normal CD34 1 cells.</s><s>However, AML with MLL rearrangements and t(8;21) had significantly lower CXXC5 expression compared with CD34 1 cells (Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>We did not have sufficient del(5q) cases to show downregulation of CXXC5 in del(5q) AML as previously reported. <ref type="bibr" target="#b16">17</ref></s><s>However, analysis of 14 selected del(5q)/-5 cases from the MRC AML17 trial confirmed significant downregulation of CXXC5 compared with CD34 1 cells (P , .001).</s><s>AML with CXXC5 expression of higher-than-normal CD34 1 cells could not be assigned to any specific subgroup.</s></p><p><s>Association of microarray-based CXXC5 expression from the HOVON/SAKK cohort (n 5 529) with clinical and molecular markers is shown in Table <ref type="table" target="#tab_1">1</ref>.</s><s>Microarray-based CXXC5 expression correlated well with RT-qPCR results (r 5 0.7; P , .001).</s><s>AML patients were grouped into lower and higher CXXC5 expressers according to the median expression level of all 3 CXXC5 probe sets.</s><s>Patients with lower CXXC5 expression had a higher incidence of MLL rearrangements (9% vs 4%; P 5 .03)</s><s>and t(8;21) (13% vs 2%; P , .001) and a lower incidence of FLT3-ITD (22% vs 32%; P 5 .01).</s><s>No significant association was seen with respect to del(5q), likely because of low patient numbers (Table <ref type="table" target="#tab_1">1</ref>).</s><s>We found correlation of CXXC5 expression with expression of MN1 (Pearson coefficient, r 5 0.2; P , .001),</s><s>WT1 (r 5 0.5; P , .001), and ERG (r 5 0.3; P , .001).</s><s>No significant association was observed with respect to mutations of CEBPA, NPM1, IDH1/2, DNMT3A, or ASXL1, nor with EVI1 and BAALC expression (data not shown).</s><s>Median CXXC5 expression was significantly higher in cases with WT1 mutation (P 5 .03).</s><s>There was no association of CXXC5 expression with age, white blood cell count, or sex (Table <ref type="table" target="#tab_1">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CXXC5-associated GEP in AML patients</head><p><s>In NK-AML (MILE data set, n 5 351), we found 659 probe sets comprising 457 genes to be differentially expressed in cases with lower vs higher CXXC5 expression (Q1 vs Q4; see Patients and methods), 295 being upregulated and 162 downregulated (supplemental Table <ref type="table" target="#tab_2">2</ref> and Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>Among the upregulated genes in the lower CXXC5 expression group were the antiapoptotic protooncogenes Survivin and BCL6, as well as genes of aurora kinase signaling (AURKA, DLGAP5, BUB1) and cell-cycling (CCNB1/2, CCNA2, CDK1, CDC20, KIF23, NEK2, UBE2C).</s><s>Downregulated genes in patients with lower CXXC5 expression included genes that have previously been related to leukemogenesis and outcome in AML (WT1, 27 GATA2, 28,29 MLL, 9 DNMT3B, 10 RUNX1, 30 MN1, 31 MIR155HG, 32 MSI2 33 ).</s><s>To validate differentially expressed genes from the MILE dataset, we also analyzed CXXC5-associated gene expression in the unselected HOVON/SAKK cohort (supplemental Table <ref type="table">3</ref>).</s><s>In total, 117 of the 295 upregulated genes and 49 of the 162 downregulated genes were confirmed in the HOVON/SAKK cohort, including WT1, GATA2, DNMT3B, RUNX1, and MSI2 (supplemental Figure <ref type="figure" target="#fig_1">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Association of CXXC5 and GATA2</head><p><s>The transcription factor GATA2, codownregulated in our GEP analysis, binds the CXXC5 promoter according to ENCODE data (UCSC  genome browser; http://genome.ucsc.edu),</s><s>suggesting regulation of CXXC5 by GATA2.</s><s>To further investigate this potential interaction, we overexpressed GATA2 in 293T cells and found upregulation of CXXC5 protein compared with vector controls (supplemental Figure <ref type="figure" target="#fig_2">3</ref>), which was confirmed at the mRNA level (mean 2.8-fold increase of CXXC5 expression compared with control; data not shown), supporting a functional interplay of both genes.</s><s>We next measured CXXC5 mRNA levels in 17 AML patients with GATA2 mutations and showed a significantly lower CXXC5 expression than in normal CD34 1 cells (median, 15 [range, 5-39]; P , .0001).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CXXC5 expression and outcome in AML</head><p><s>In 498 patients from the HOVON/SAKK cohort (APL excluded) analyzed for outcome, patients with lower CXXC5 expression (below the median expression level) had a trend to a higher complete remission (CR) rate (84% vs 77%; P 5 .07)</s><s>and a lower relapse rate compared with patients with higher CXXC5 expression (45% vs 59% at 5 years; P 5 .007).</s><s>Overall survival (OS) and event-free survival (EFS) were significantly better in lower compared with higher CXXC5-expressing AML cases (5-year OS: 95% confidence interval [CI], 46% [40%-52%] vs 28% [22%-34%]; P , .001;</s><s>5-year EFS: 36% [30%-42%] vs 21% [16%-26%]; P , .001; Figure <ref type="figure" target="#fig_1">2A</ref>).</s><s>The prognostic significance of CXXC5 was independent of known clinical and molecular risk factors in multivariate analyses (Table <ref type="table" target="#tab_2">2</ref>).</s><s>There was no significant heterogeneity in the impact of CXXC5 on outcome between AML risk groups (supplemental Figure <ref type="figure" target="#fig_3">4</ref>).</s><s>CXXC5 was also significant for OS and EFS when treated as a continuous variable (data not shown).</s><s>A significant impact of CXXC5 expression on OS and EFS was confirmed in the cohort of 231 AML patients using RT-qPCR median expression values (Figure <ref type="figure" target="#fig_1">2B</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CXXC5 impairs the canonical Wnt pathway</head><p><s>Because CXXC5 is known to inhibit the canonical Wnt pathway in nontumorous cells, we determined its impact on Wnt signaling in leukemic cell lines.</s><s>Overexpression of CXXC5 in K562 and KG1a cells attenuated upregulation of total b-catenin and active b-catenin 5 hours after Wnt3a stimulation compared with vector controls (Figure <ref type="figure" target="#fig_2">3A</ref>).</s><s>Moreover, upregulation of Wnt target genes Axin2 and Survivin by Wnt3a was significantly decreased after expression of CXXC5 in both cell lines as determined by RT-qPCR (Figure <ref type="figure" target="#fig_2">3B</ref>).</s><s>In addition, we evaluated differences in Wnt activation by Wnt reporter assay.</s><s>CXXC5 expression resulted in decreased luciferase activity after Wnt3a stimulation in K562 and KG1a compared with vector controls (Figure <ref type="figure" target="#fig_2">3C</ref>).</s><s>Overexpression of CXXC5 led to a significant decrease in proliferation of K562, KG1a, and HL60 cells treated with Wnt3a protein as determined by cell count and MTT assay (Figure <ref type="figure" target="#fig_2">3D</ref>).</s><s>This was accompanied by increased apoptosis measured by Annexin V staining (data not shown).</s><s>Accordingly, knockdown of CXXC5 (supplemental Figure <ref type="figure" target="#fig_4">5</ref>) resulted in increased proliferation of Wnt-stimulated cells (Figure <ref type="figure" target="#fig_2">3D</ref>).</s><s>Without concomitant Wnt3a treatment, cell proliferation was only moderately decreased in K562 and HL60 cells overexpressing CXXC5, but was not significantly changed in KG1a or in any of the CXXC5 knockdown cells (data not shown).</s></p><p><s>Previous studies suggested that CXXC5 interacts with disheveled (Dvl) proteins as a mechanism of Wnt inhibition. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b4">5</ref></s><s>However, we did not observe colocalization of EGFP-tagged CXXC5 with endogenous Dvl1, Dvl2, or Dvl3 in confocal microscopy or binding in immunoprecipitation experiments in K562 (data not shown).</s></p><p><s>To gain further insights into the cellular pathways involved in the interaction of CXXC5 with Wnt signaling, we conducted microarraybased GEP on Wnt-stimulated K562 cells after overexpression and knockdown of CXXC5, respectively (supplemental Table <ref type="table">4</ref>).</s><s>We found a substantial overlap of differentially expressed genes in both models: 77 of 186 upregulated genes in CXXC5-overexpressing cells showed corresponding downregulation in knockdown cells.</s><s>Similarly, 65 of 137 downregulated genes in CXXC5-overexpressing cells were upregulated in CXXC5 knockdown cells.</s><s>Several signaling pathways were significantly enriched in both CXXC5-overexpressing and knockdown cells, such as TRAIL, c-MYC, mTOR, and IGF1 (supplemental Figure <ref type="figure">6</ref>).</s><s>We found Wnt target genes Survivin, TPM1, SRSF3, MET, HES1, and FSCN1 to be upregulated in CXXC5 knockdown cells, indicating activated Wnt signaling.</s><s>HES1 expression was accordingly downregulated in CXXC5-overexpressing cells.</s><s>Wnt repressors HBP1 and AXIN1 were upregulated in cells overexpressing CXXC5 (1.6-fold [P 5 .001]</s><s>and 1.2-fold [P # .0001])</s><s>and accordingly downregulated in knockdown cells (1.7-fold [P 5 .001]</s><s>and 1.4-fold [P 5 .003]).</s><s>In addition, CXXC5-knockdown cells showed significant upregulation of Wnt activators CAV1 and APPL1 (supplemental Table <ref type="table">4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Knockdown of CXXC5 reduces p53 activation and cell-cycle arrest upon DNA damage</head><p><s>Because CXXC5 has been shown to affect p53 signaling, <ref type="bibr" target="#b2">3</ref> we performed cell-cycle analyses after g-irradiation of OCI-AML3 cells (harboring wild-type p53) to see whether knockdown of CXXC5 alters the p53dependent DNA damage response in leukemic cells.</s><s>OCI-AML3 stably infected with lentiviral CXXC5 shRNA clones TRCN0000144558 and TRCN0000142729 showed a reduced and delayed G1 and a reduced G2 arrest after irradiation with 4 Gy (Figure <ref type="figure" target="#fig_3">4A</ref>).</s><s>In addition, irradiation-induced upregulation of p53 protein was decreased after CXXC5 knockdown compared with controls (Figure <ref type="figure" target="#fig_3">4B</ref>).</s><s>This was accompanied by impaired nuclear translocation of p53 (Figure <ref type="figure" target="#fig_3">4C</ref>).</s><s>Knockdown of CXXC5 in K562 (p53 deficient) did not alter cellcycle distribution after irradiation (data not shown), further underlining the p53-dependent impact of CXXC5 on DNA-damage response in leukemic cells.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mutational analyses of CXXC5</head><p><s>We performed DNA sequencing of CXXC5 in 84 AML patients to investigate the presence of CXXC5 mutations.</s><s>No CXXC5 mutations were found, suggesting that deregulation of CXXC5 by gene mutations plays no major role in AML.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Association of CXXC5 expression with promoter methylation</head><p><s>To evaluate epigenetic silencing as a mechanism of CXXC5 downregulation in AML, we conducted pyrosequencing in 46 AML samples and 6 normal CD34 1 samples at 4 different regions of the CXXC5 promoter (#1-3) and intron 1 (#4; Figure <ref type="figure" target="#fig_4">5A</ref>).</s><s>In AML, the degree of methylation of region #2 was inversely correlated with CXXC5 mRNA expression levels (r 5 20.32; P 5 .03).</s><s>A higher degree of methylation at regions #1 and #2 was observed in cases harboring IDH1/2 mutations (median, 42% vs 15%; P 5 .004;</s><s>and median, 29% vs 12%; P 5 .05,</s><s>respectively), whereas methylation at region #2 was lower in cases with DNMT3A mutations (9% vs 20%; P 5 .05).</s><s>There was no correlation between mutation status and gene expression, although sample numbers were small.</s><s>No relationship was observed between the mutational status of other genes in the panel and methylation, including WT1, TET2, and ASXL1 (see supplemental Figure <ref type="figure">7</ref>).</s></p><p><s>We tested methylation of region #2 in different leukemic cell lines.</s><s>KG1a, K562, and HEL cells were unmethylated (,3%), whereas Kasumi-1 (24%), NB4 (68%), and U937 (95%) showed a high degree of methylation.</s></p><p><s>To investigate epigenetic regulation of CXXC5 at region #2, we treated the highly methylated cell lines U937 and NB4 with 0.2 mM *Variables considered for model inclusion were (see supplemental Material for details): CXXC5 expression (below vs above median level), cytogenetic risk groups (good, intermediate, unfavorable), age (10-year increase), WBC (10/nl increase), FLT3-ITD 34 /NPM1 wild-type (present vs absent), NPM1 mutation 35 /FLT3-ITD negative (present vs absent), CEBPA biallelic mutation <ref type="bibr" target="#b36">36</ref> (present vs absent), DNMT3A mutation <ref type="bibr" target="#b37">37</ref> (present vs absent), ASXL1 mutation <ref type="bibr" target="#b38">38</ref> (present vs absent), WT1 mutation (present vs absent), WT1 expression (lower vs higher than median).</s></p><p><s>†Below median expression level.</s></p><p><s>DAC.</s><s>After 96 hours, mean methylation at region #2 was markedly decreased and CXXC5 expression was increased 1.8-fold and 2.9-fold in U937 and NB4, respectively (both P , .05; Figure <ref type="figure" target="#fig_4">5B</ref>), suggesting silencing of CXXC5 by promoter hypermethylation in AML.</s><s>This was also reflected at the protein level (supplemental Figure <ref type="figure">8</ref>).</s><s>No change in CXXC5 expression was seen when cells were treated with 1 to 50 nM cytarabine and no effect was observed in unmethylated KG1a and K562 cells (data not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Identification of prognostically relevant leukemic pathways in AML provides novel insights into disease pathogenesis and may inform targeted therapy approaches.</s><s>Aberrant CXXC5 expression has recently been described in a small cohort of AML, and preliminary data suggested an impact of CXXC5 expression on outcome. <ref type="bibr" target="#b21">21</ref></s><s>Here, we found evidence for a tumor-suppressor function of CXXC5 in AML and demonstrated its independent prognostic significance.</s><s>Investigating CXXC5 expression in the HOVON/SAKK multicenter AML trial cohort, we showed that CXXC5 was significantly downregulated in AML with MLL rearrangements and t (8;21).</s><s>Downregulation of CXXC5 has previously been reported in 22 AML/ high-risk MDS patients with del(5q), <ref type="bibr" target="#b16">17</ref> in accordance with our experimental findings.</s></p><p><s>GEP analyses further revealed that CXXC5 expression was codownregulated with genes for which inactivating mutations or silencing of the wild-type allele/protein have been implicated in leukemogenesis and cancer development, such as GATA2, <ref type="bibr" target="#b28">28,</ref><ref type="bibr" target="#b29">29</ref> MLL, 39 DNMT3B, <ref type="bibr" target="#b40">40</ref> and RUNX1, <ref type="bibr" target="#b30">30,</ref><ref type="bibr" target="#b41">41</ref> which is in line with a recent study investigating a single-center cohort of 48 AML cases. <ref type="bibr" target="#b42">42</ref></s><s>We investigated 17 AML samples with GATA2 mutations and found CXXC5 expression to be significantly downregulated.</s><s>We further demonstrated that overexpression of GATA2 leads to upregulation of CXXC5, suggesting transcriptional regulation of CXXC5 by GATA2, which is in line with published ENCODE data.</s><s>Thus, low expression of CXXC5 might be a common downstream effect of different leukemic pathways, including GATA2 mutations.</s></p><p><s>We demonstrated that CXXC5 attenuates Wnt signaling in leukemic cell lines, a crucial pathway for leukemic self-renewal and survival. <ref type="bibr" target="#b7">8</ref></s><s>Downregulation of CXXC5 might therefore contribute to leukemogenesis by promoting Wnt signaling.</s><s>Wnt inhibition by CXXC5 has been described in nontumorous tissue, and interaction of CXXC5 with Dvl proteins was identified as an underlying mechanism. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b4">5</ref></s><s>Here, we did not observe interaction of CXXC5 with Dvl proteins.</s><s>This might be explained by the fact that in the leukemic cell lines tested, CXXC5 (EGFP-tagged and endogenous protein) was predominantly localized in the nucleus, in accordance with in silico analyses and results in NB4, HeLa, and MCF7 cells. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b20">20</ref></s><s>In contrast, Kim et al and Andersson et al found CXXC5 (and its interaction with Dvl) localized in the cytoplasm. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b4">5</ref></s><s>Thus, interaction of CXXC5 with Dvl proteins and its relevance for Wnt attenuation might strongly depend on the cellular context.</s><s>Interestingly, Kim et al demonstrated that the ability of CXXC5 to bind Dvl was less important for Wnt inhibition than presence of the CXXC domain, further suggesting other mechanisms of inhibition. <ref type="bibr" target="#b3">4</ref> It has been shown that CXXC5 interacts with the vitamin D receptor, <ref type="bibr" target="#b43">43</ref> which could lead to Wnt suppression.</s><s>In our GEP analysis of Wnt-stimulated K562 cells, we identified Wnt repressors HBP1 and AXIN1 significantly altered by CXXC5 expression, which could mediate CXXC5associated effects on Wnt signaling.</s></p><p><s>Small molecules targeting the Wnt pathway exhibited marked antileukemic activity in vitro, <ref type="bibr" target="#b44">44</ref> and there is recent evidence that Wnt inhibition is particularly effective in leukemic cells with del(5q). <ref type="bibr" target="#b45">45</ref></s><s>herefore, AML patients with low CXXC5 expression might be candidates for Wnt inhibitor treatment.</s></p><p><s>In MCF7 and HeLa cells containing wild-type p53, CXXC5 has been shown to promote p53 signaling through binding of ATM kinase with its CXXC domain. <ref type="bibr" target="#b2">3</ref></s><s>Similarly, in our study, inactivation of CXXC5 impaired p53-dependent cell-cycle arrest after DNA damage.</s><s>Low CXXC5 expression might thus increase genomic instability in AML.</s><s>In GEP analysis, several cell-cycle genes (CCNB1/2, CCNA2, CDK1, CDC2, CDC20, KIF23) were upregulated in patients with low CXXC5 expression, further suggesting involvement of CXXC5 in cellcycle processes in leukemia.</s><s>Lower expression of CXXC5 predicted a lower relapse rate and better long-term survival in AML patients.</s><s>Our results confirm data from Astori et al who performed univariate outcome analyses on 2 German AML trial cohorts using published microarray data. <ref type="bibr" target="#b21">21</ref></s><s>In addition, a recent study related overexpression of CXXC5 to inferior OS in breast cancer. <ref type="bibr" target="#b46">46</ref></s><s>In our analysis, low expression of CXXC5 was associated with known prognostic factors (higher frequency of MLL rearrangements and t(8;21) and lower frequency of FLT3-ITD), but its prognostic impact remained significant in multivariate analyses after adjustment for these factors.</s><s>Thus, CXXC5 expression defines a subgroup of AML with distinct outcome independent of other cytogenetic and molecular markers.</s><s>It is unclear why lower CXXC5 expression with its activating function on Wnt signaling confers a better prognosis, because Wnt activation has been associated with inferior outcome in AML. <ref type="bibr" target="#b47">47</ref></s><s>However, it has recently been shown that high expression of LEF1, a key activator of Wnt signaling, is associated with a better prognosis in AML. <ref type="bibr" target="#b48">48</ref></s><s>Moreover, other functions of CXXC5 than Wnt regulation may be relevant for prognosis and might increase chemosensitivity. <ref type="bibr" target="#b21">21,</ref><ref type="bibr" target="#b42">42</ref></s><s>n accordance with previous studies, we did not find any mutation of CXXC5 in AML.</s><s>Genetic alterations of CXXC5 seem to be rare, and infrequent, small intragenic deletions as described in a patient with NK-AML, <ref type="bibr" target="#b17">18</ref> or haploinsufficiency due to del(5q), cannot explain the wide range of expression seen in AML.</s><s>Treppendahl et al found that several cases with del(5q) had ,50% CXXC5 expression levels, suggesting additional mechanisms of inactivation than haploinsufficiency. 17</s><s>WT1 has been shown to regulate CXXC5 expression <ref type="bibr" target="#b3">4</ref> and was indeed strongly correlated with CXXC5 expression in our GEP analysis.</s><s>In addition, we found evidence for silencing of CXXC5 by promoter hypermethylation.</s><s>Of note, this was only evident in 1 region of the CpG shore (2914 to 2741), not in other regions of the CXXC5 promoter, which could explain negative results of a previous CXXC5 methylation analysis, investigating a site further upstream (220440 to 220330). 17</s><s>Thus, epigenetic modification as well as transcriptional regulation by factors like GATA2 and WT1 might contribute to aberrant CXXC5 expression in AML.</s></p><p><s>Further studies are needed to investigate mechanisms of CXXC5 regulation, the spectrum of molecular interactions of CXXC5, and its role in leukemic pathways, particularly in cases with MLL rearrangements and t (8;21).</s><s>Recent studies demonstrated that CXXC5 binds DNA and acts as a transcriptional activator as well as a repressor. <ref type="bibr" target="#b49">49</ref></s><s>In addition, the CXXC5 paralog CXXC4 was shown to bind unmethylated CpG-rich DNA and interact with TET2, and a similar role was postulated for CXXC5. <ref type="bibr" target="#b50">50</ref></s><s>n summary, we have investigated the 5q31 gene CXXC5 in AML with respect to clinical characteristics and prognosis and gene expression and its functional implications.</s><s>Our data suggest a role of CXXC5 as a tumor suppressor in different AML subgroups.</s><s>Inactivation of CXXC5 characterizes AML with a better outcome, which might be particularly sensitive to Wnt inhibitor treatment.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>CXXC5 mRNA expression in AML and control samples.</s><s>CXXC5 expression was determined in 231 HOVON/SAKK AML cases and 19 normal CD34 1 by RT-qPCR, calculating the mean cycle threshold difference (ΔCT) to ABL, expressed as 2 ΔCt .</s><s>Jurkat RNA was used as a calibrator between runs.</s><s>Horizontal lines indicate median expression values.</s><s>CXXC5 expression in cases with t(8;21) and MLL rearrangements was significantly lower compared with CD34 1 controls.</s><s>The other subgroups, including cases with biallelic mutations of CEBPA or mutations involving NPM1, DNMT3A, and ASXL1 genes, showed no significant difference in CXXC5 expression compared with CD34 1 controls.</s><s>"Complex karyotype other" indicates cases with complex karyotype without del(5q) or del(7q).</s><s>**P # .01,</s><s>***P # .001</s><s>by the Mann-Whitney U test.</s></p></div></figDesc><graphic coords="3,308.24,454.45,226.36,189.87" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Overall survival (OS) and event-free survival (EFS) in HOVON/SAKK AML patients according to CXXC5 expression.</s><s>(A) Survival according to microarraybased CXXC5 expression (n 5 498).</s><s>CXXC5 expression below the median (lower): median OS of 30 months (95% CI, 4-57); CXXC5 expression above the median (higher): median OS of 15 months (95% CI, 12-18).</s><s>CXXC5 lower: median EFS of 14 months (95% CI, 10-18); CXXC5 higher: median EFS of 9 months (95% CI, 7-10).</s><s>(B) Survival according to RT-qPCR expression (n 5 231).</s><s>Lower and higher CXXC5 expression groups were defined according to the median CXXC5 expression value, determined by the mean cycle threshold difference (ΔCT) to ABL, expressed as 2 ΔCt .</s><s>Jurkat RNA was used to calibrate between runs.</s><s>CXXC5 was more highly expressed than ABL, with a ΔCT of 2.3 at the median CXXC5 level.</s></p></div></figDesc><graphic coords="4,57.49,66.84,476.95,380.24" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3. CXXC5 attenuates Wnt signaling in leukemic cells.</s><s>Cells overexpressing EGFP-tagged CXXC5 or stably infected with lentiviral CXXC5 shRNA were treated with 100 ng/mL recombinant Wnt3a.</s><s>(A) Decreased upregulation of total b-catenin and active b-catenin 5 hours after Wnt3a treatment in CXXC5-overexpressing cells compared with vector controls (Western blot analysis).</s><s>A representative figure is shown (transfection efficiency of 59% for K562 and 42% for KG1a by flow cytometry).</s><s>(B) Decreased upregulation of Wnt target genes Axin2 and Survivin 10 hours after Wnt3a treatment in CXXC5-overexpressing cells compared with vector controls as determined by RT-qPCR.</s><s>Mean values of 2 independent experiments with standard deviations are shown (K562 Axin2: 1.4-fold vs 3.1-fold; K562 Survivin: 0.9-fold vs 1.2-fold; KG1a Axin2: 0.7fold vs 1.7-fold; KG1a Survivin: 0.6-fold vs 1.3-fold; both P # .05</s><s>by the Mann-Whitney U test[*]).</s><s>(C) Impaired Wnt activation as determined by Wnt reporter assay activity 5 hours after Wnt3a treatment in CXXC5-overexpressing cells compared with vector controls.</s><s>Mean values of 2 independent experiments with standard deviations are shown (K562: 4.7-fold vs 19.9-fold; KG1a: 0.9-fold vs 2.8-fold; *P # .05 and **P # .01 by the Mann-Whitney U test).</s><s>(D) Impaired cell proliferation after CXXC5 overexpression (i, iii) and increased proliferation after CXXC5 knockdown (ii, iv) as determined by cell count (trypan blue staining; iii-iv) and MTT assay (i-ii) 24, 48, and 72 hours after start of treatment (days 1-3).</s><s>Wnt3a protein was replaced every 24 hours.</s><s>Mean values of 2 independent experiments performed in quadruplicates with standard deviations are shown.</s><s>Co, vector control; scr, scrambled shRNA control; shR, CXXC5 shRNA.</s><s>P values are shown in the figure (**P # .01 and ***P # .001</s><s>by the Mann-Whitney U test).</s></p></div></figDesc><graphic coords="6,57.03,66.84,478.04,508.71" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 .</head><label>4</label><figDesc><div><p><s>Figure 4. Inhibition of DNA damage-induced cell-cycle arrest and p53 activation after knockdown of CXXC5 in OCI-AML3 cells.</s><s>Cells were stably infected with lentiviral CXXC5 shRNA (shR) or scrambled control (co) and irradiated with 4 Gy.</s><s>(A) Reduced and delayed G1 and G2 arrest after irradiation compared with controls.</s><s>A representative figure is shown.</s><s>Numbers in bars correspond to percentages of cells.</s><s>(B) Decreased upregulation of p53 protein 4 hours after irradiation compared with control as determined by Western blot.</s><s>A representative blot is shown.</s><s>The 2 bands for CXXC5 correspond to the 24-kDa and 33-kDa isoforms.</s><s>(C) Decreased upregulation and nuclear localization of p53 protein 4 hours after irradiation compared with control in confocal microscopy.</s><s>Representative images are shown.</s><s>Original magnification 360 for all images.</s></p></div></figDesc><graphic coords="7,57.03,66.84,478.04,243.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 5 .</head><label>5</label><figDesc><div><p><s>Figure 5. Epigenetic regulation of CXXC5.</s><s>(A) Schematic figure of methylation analysis by pyrosequencing within the CXXC5 gene and median methylation values (with range) for AML samples (n 5 46) and healthy controls (normal BM CD34 1 cells, n 5 6).</s><s>CDS, coding region; CpG, CpG island; E1-3, 3 CXXC5 exons.</s><s>Four different regions in the CXXC5 promoter (#1-3) and intron 1 (#4) were analyzed: (#1) 21343 to 21213 (2 CpGs); (#2) 2914 to 2741 (3 CpGs); (#3) 2749 to 2593 (5 CpGs); (#4) 11955 to 12179 (4 CpGs).</s><s>The previous study of Treppendahl et al 17 investigated a site further upstream in the CXXC5 promoter (220 440 to 220 330, personal communication Marianne Treppendahl, Department of Hematology, Rigshospitalet Copenhagen, Denmark).</s><s>Methylation of region #2 was significantly higher in AML than in healthy controls (P 5 .04);</s><s>methylation of region #3 was significantly lower (P 5 .001).</s><s>No difference between AML and controls was observed in the other 2 regions.</s><s>P values were calculated by the Mann-Whitney U test.</s><s>(B) Upregulation of CXXC5 after demethylation of region #2.</s><s>U937 and NB4 cells were treated with 5-Aza-29-deoxycytidine (DAC) for 96 hours and CXXC5 expression was determined by RT-qPCR.</s><s>Values are normalized to dimethyl sulfoxide control.</s><s>Mean values of 2 independent experiments with standard deviations are shown (*P # .05</s><s>by the Mann-Whitney U test).</s><s>Demethylation of region #2 was confirmed by pyrosequencing and mean methylation percentages of 2 independent experiments are shown.</s></p></div></figDesc><graphic coords="8,57.03,66.84,478.04,310.39" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc><div><p><s>(see supplemental Material, available on the Blood Web site; median age, 46 years [range, 15-77]).</s><s>Samples contained at least 80% blasts.</s><s>From 231 cases of this cohort (median age, 48 years [range,</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Clinical and molecular characteristics according to CXXC5 expression in AML in the HOVON/SAKK cohort</s></p></div></figDesc><table><row><cell></cell><cell>CXXC5 lower</cell><cell>CXXC5 higher</cell><cell></cell></row><row><cell>Characteristic</cell><cell>(n 5 264)</cell><cell>(n 5 265)</cell><cell>P</cell></row><row><cell>Age, y</cell><cell></cell><cell></cell><cell>.64</cell></row><row><cell>Median</cell><cell>46</cell><cell>47</cell><cell></cell></row><row><cell>Range</cell><cell>15-77</cell><cell>15-77</cell><cell></cell></row><row><cell>Sex, %</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Male</cell><cell>50</cell><cell>50</cell><cell>1.0</cell></row><row><cell>WBC, 310 9 /L</cell><cell></cell><cell></cell><cell>.89</cell></row><row><cell>Median</cell><cell>28</cell><cell>29</cell><cell></cell></row><row><cell>Range</cell><cell>0.3-510</cell><cell>0.8-274</cell><cell></cell></row><row><cell>Cytogenetics, %*</cell><cell></cell><cell></cell><cell></cell></row><row><cell>t(8;21); RUNX1-RUNX1T1</cell><cell>13</cell><cell>2</cell><cell>,.001</cell></row><row><cell>inv(16) or t(16;16); CBFB-MYH11</cell><cell>10</cell><cell>6</cell><cell>.15</cell></row><row><cell>11q23</cell><cell>9</cell><cell>4</cell><cell>.03</cell></row><row><cell>t(6;9); DEK-NUP214</cell><cell>1</cell><cell>1</cell><cell>1 . 0</cell></row><row><cell>inv(3) or t(3;3); RPN1-EVI1</cell><cell>1</cell><cell>3</cell><cell>.14</cell></row><row><cell>del(5q)</cell><cell>1</cell><cell>1</cell><cell>.68</cell></row><row><cell>Other adverse</cell><cell>9</cell><cell>12</cell><cell>.57</cell></row><row><cell>Normal karyotype</cell><cell>37</cell><cell>48</cell><cell>.02</cell></row><row><cell>Molecular genetics, % †</cell><cell></cell><cell></cell><cell></cell></row><row><cell>FLT3-ITD</cell><cell>22</cell><cell>32</cell><cell>.01</cell></row><row><cell>NPM1 mutated</cell><cell>30</cell><cell>31</cell><cell>.92</cell></row><row><cell>WBC, white blood cell.</cell><cell></cell><cell></cell><cell></cell></row><row><cell>*N 5 510.</cell><cell></cell><cell></cell><cell></cell></row><row><cell>†N 5 522.</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Multivariate analyses for CXXC5 expression</s></p></div></figDesc><table><row><cell>Variable*</cell><cell>OR/HR</cell><cell>95% CI</cell><cell>P</cell></row><row><cell>Relapse rate</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Low CXXC5 †</cell><cell>0.5</cell><cell>0.3-0.8</cell><cell>.007</cell></row><row><cell>Cytogenetic risk</cell><cell>1.9</cell><cell>1.2-2.9</cell><cell>.005</cell></row><row><cell>WBC</cell><cell>1.06</cell><cell>1.0-1.1</cell><cell>.005</cell></row><row><cell>CEBPA mut., biallelic</cell><cell>0.4</cell><cell>0.2-1.0</cell><cell>.05</cell></row><row><cell>ASXL1 mut.</cell><cell>9.5</cell><cell>2.0-45</cell><cell>.004</cell></row><row><cell>Overall survival</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Low CXXC5 †</cell><cell>0.6</cell><cell>0.5-0.8</cell><cell>.001</cell></row><row><cell>Cytogenetic risk</cell><cell>1.7</cell><cell>1.3-2.1</cell><cell>,.001</cell></row><row><cell>Age</cell><cell>1.2</cell><cell>1.0-1.3</cell><cell>.004</cell></row><row><cell>FLT3-ITD/NPM1 wt</cell><cell>1.7</cell><cell>1.2-2.5</cell><cell>.004</cell></row><row><cell>NPM1 mut./FLT3-ITD neg.</cell><cell>0.6</cell><cell>0.4-0.8</cell><cell>.006</cell></row><row><cell>CEBPA mut., biallelic</cell><cell>0.3</cell><cell>0.2-0.6</cell><cell>,.001</cell></row><row><cell>DNMT3A mut.</cell><cell>1.4</cell><cell>1.1-2.0</cell><cell>.02</cell></row><row><cell>ASXL1 mut.</cell><cell>1.6</cell><cell>1.0-2.5</cell><cell>.04</cell></row><row><cell>Event-free survival</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Low CXXC5 †</cell><cell>0.6</cell><cell>0.5-0.8</cell><cell>,.001</cell></row><row><cell>Cytogenetic risk</cell><cell>1.6</cell><cell>1.3-2.0</cell><cell>,.001</cell></row><row><cell>WBC</cell><cell>1.02</cell><cell>1.0-1.0</cell><cell>.04</cell></row><row><cell>FLT3-ITD/NPM1 wt</cell><cell>1.7</cell><cell>1.2-2.5</cell><cell>.006</cell></row><row><cell>NPM1 mut./FLT3-ITD neg.</cell><cell>0.6</cell><cell>0.4-0.9</cell><cell>.009</cell></row><row><cell>CEBPA mut., biallelic</cell><cell>0.3</cell><cell>0.2-0.6</cell><cell>,.001</cell></row><row><cell>DNMT3A mut.</cell><cell>1.4</cell><cell>1.0-1.8</cell><cell>.04</cell></row><row><cell>ASXL1 mut.</cell><cell>2.0</cell><cell>1.2-3.2</cell><cell>.005</cell></row></table><note><p><s>CI, confidence interval; HR, hazard ratio; mut., mutated; neg., negative; OR, odds ratio; WBC, white blood cell count; wt, wild-type.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">K ÜHNL et al BLOOD, 7 MAY 2015 x VOLUME 125, NUMBER 19 Downloaded from http://ashpublications.org/blood/article-pdf/125/19/2985/1385005/2985.pdf by guest on 17 May 2022</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Downloaded from http://ashpublications.org/blood/article-pdf/125/19/2985/1385005/2985.pdf by guest on 17 May 2022</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>The authors thank the FACS core facility at Guy's Hospital, London, for support with flow cytometry and the BRC Genomics Laboratory, King's College London for enabling high-throughput mutational analyses.</s><s>The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.</s><s>Immunofluorescence was conducted at the Nikon Imaging Centre at King's College London.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Correspondence: David Grimwade, Department of Medical &amp; Molecular Genetics, 8th Floor, Tower Wing, Guy's Hospital, London SE1 9RT, United Kingdom; e-mail: david.grimwade@genetics.kcl.ac.uk.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Therapeutic advances in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Burnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wetzler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="487" to="494" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">United Kingdom National Cancer Research Institute Haematological Oncology Study Group. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Burnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Milligan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Goldstone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="318" to="332" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The CXXC finger 5 protein is required for DNA damageinduced p53 activation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci China C Life Sci</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="528" to="538" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">A novel Wilms tumor 1 (WT1) target gene negatively regulates the WNT signaling pathway</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bollig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">285</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="14585" to="14593" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">CXXC5 is a novel BMP4-regulated modulator of Wnt signaling in neural stem cells</title>
		<author>
			<persName><forename type="first">T</forename><surname>Andersson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Duckworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">284</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="3672" to="3681" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Krivtsov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">U</forename><surname>Sinha</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">327</biblScope>
			<biblScope unit="issue">5973</biblScope>
			<biblScope unit="page" from="1650" to="1653" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">L</forename><surname>Grandage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Linch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Khwaja</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="2410" to="2420" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Üller-Tidow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Steffen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Cauvet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="2890" to="2904" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Ayton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Cleary</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">40</biblScope>
			<biblScope unit="page" from="5695" to="5707" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mizuno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Chijiwa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Okamura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1172" to="1179" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Trowbridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">U</forename><surname>Sinha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Orkin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genes Dev</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="344" to="349" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing</title>
		<author>
			<persName><forename type="first">A</forename><surname>Dolnik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Engelmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Scharfenberger-Schmeer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="e83" to="e92" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23)</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Lorsbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mathew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Raimondi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Mukatira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Downing</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="637" to="641" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">DNMT3A mutations in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Ley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Walter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope unit="issue">25</biblScope>
			<biblScope unit="page" from="2424" to="2433" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies</title>
		<author>
			<persName><forename type="first">Abdel-Wahab O</forename><surname>Mullally</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hedvat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="144" to="147" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kojima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Shimazui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hinotsu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="297" to="305" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q</title>
		<author>
			<persName><forename type="first">M</forename><surname>Treppendahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mollgard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hellstrom-Lindberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cloos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gronbaek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Haematol</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="259" to="260" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Murati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gervais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Carbuccia</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Groupe Francophone de Cytog én étique H ématologique. Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases</title>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="85" to="94" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia</title>
		<author>
			<persName><forename type="first">V</forename><surname>Gelsi-Boyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Trouplin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ad Élaïde</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="788" to="800" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis</title>
		<author>
			<persName><forename type="first">F</forename><surname>Pendino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Jonassen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="3172" to="3181" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Astori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fredly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Aloysius</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1438" to="1448" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Prognostically useful gene-expression profiles in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Valk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Verhaak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Beijen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">350</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="1617" to="1628" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Verhaak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Wouters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Erpelinck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="131" to="134" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group</title>
		<author>
			<persName><forename type="first">T</forename><surname>Haferlach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kohlmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wieczorek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="2529" to="2537" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy</title>
		<author>
			<persName><forename type="first">D</forename><surname>Grimwade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Jovanovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Hills</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="3650" to="3658" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using &apos;real-time&apos; quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) -a Europe Against Cancer program</title>
		<author>
			<persName><forename type="first">E</forename><surname>Beillard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Pallisgaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">H</forename><surname>Van Der Velden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2474" to="2486" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia</title>
		<author>
			<persName><forename type="first">C</forename><surname>Owen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fitzgibbon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Paschka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hematol Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="13" to="19" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">N</forename><surname>Hahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Chong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Carmichael</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1012" to="1017" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Greif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dufour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Konstandin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="395" to="403" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="issue">26</biblScope>
			<biblScope unit="page" from="5352" to="5361" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics</title>
		<author>
			<persName><forename type="first">M</forename><surname>Heuser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Beutel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Krauter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3898" to="3905" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">R</forename><surname>Garzon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Volinia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="3183" to="3189" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Byers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Currie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Tholouli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Rodig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Kutok</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2857" to="2867" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Care</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Valk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Goodeve</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="775" to="777" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Verhaak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Goudswaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Van Putten</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3747" to="3754" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Wouters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Erpelinck-Verschueren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Van Putten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Valk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Delwel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="3088" to="3091" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Ribeiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pratcorona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Erpelinck-Verschueren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="5824" to="5831" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value</title>
		<author>
			<persName><forename type="first">M</forename><surname>Pratcorona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Abbas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Sanders</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="388" to="392" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Whitman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Vukosavljevic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="345" to="352" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Ostler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Payne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">38</biblScope>
			<biblScope unit="page" from="5553" to="5563" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome</title>
		<author>
			<persName><forename type="first">M</forename><surname>Nakao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Horiike</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fukushima-Nakase</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="709" to="719" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells -high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation</title>
		<author>
			<persName><forename type="first">Ø</forename><surname>Bruserud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Reikvam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fredly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="2794" to="2811" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Discovery of novel vitamin D receptor interacting proteins that modulate 1,25-dihydroxyvitamin D3 signaling</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Marshall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Hernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kaneko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Steroid Biochem Mol Biol</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="issue">1-2</biblScope>
			<biblScope unit="page" from="147" to="159" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Minke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Staib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Puetter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Haematol</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="165" to="175" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Growth inhibition of a myeloid leukemia cell line with 5q deletion by beta-catenin inhibition</title>
		<author>
			<persName><forename type="first">Awq</forename><surname>Seba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ming</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Qian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>Abstract 3608</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Knappskog</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Myklebust</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Busch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2208" to="2215" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ysebaert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Chicanne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Demur</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1211" to="1216" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Metzeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Heilmeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Edmaier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2118" to="2126" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Oxygendependent expression of cytochrome c oxidase subunit 4-2 gene expression is mediated by transcription factors RBPJ, CXXC5 and CHCHD2</title>
		<author>
			<persName><forename type="first">S</forename><surname>Aras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Pak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sommer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="2255" to="2266" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>An</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Bandukwala</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">497</biblScope>
			<biblScope unit="issue">7447</biblScope>
			<biblScope unit="page" from="122" to="126" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
